The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
 
Neil J. Shah
Consulting or Advisory Role - Merck Sharp & Dohme Corp.
Research Funding - Aravive (Inst)
 
Sneha Sura
Employment - Ontada/McKesson
 
Reshma Shinde
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Junxin Shi
Employment - Mckesson
 
Rodolfo F. Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Singhal Puneet
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Nicholas J. Robert
Employment - McKesson
Leadership - McKesson
Stock and Other Ownership Interests - Johnson & Johnson (I); McKesson; Moderna Therapeutics; Oncolytics (I)
Honoraria - Bristol-Myers Squibb; Roche
Consulting or Advisory Role - Advi; Boehringer Ingelheim; Bristol-Myers Squibb; New Century Health
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Merck; Novartis; Pfizer; UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Caris Life Sciences; Clovis Oncology; Corvus Pharmaceuticals; Eisai; Genentech/Roche; Janssen Oncology; Merck; Modra Pharmaceuticals; Myovant Sciences; on quality; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Myovant Sciences; Sanofi; Seattle Genetics/Astellas
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst)
Expert Testimony - Novartis
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; Sanofi/Aventis; US Oncology
 
Robert J. Motzer
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb